{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-141847","form_type":"8-K","ticker":null,"cik":"0001828522","company_name":"eFFECTOR Therapeutics, Inc.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.465749+00:00","generated_at":"2026-06-01T16:47:03.784299+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"eFFECTOR receives Nasdaq notice for MVLS below $35M; 180-day cure period until Nov 12, 2024","bullets":["Notice dated May 16, 2024 for failure to meet $35M minimum value of listed securities for 30 consecutive business days.","Company has until November 12, 2024 to regain compliance by closing at $35M+ for 10 consecutive business days.","If non-compliant, Nasdaq may delist common stock (EFTR) and warrants (EFTRW).","Alternative compliance standard: maintain minimum stockholders' equity of $2.5M under Rule 5550(b)(1).","Management evaluating options but cannot assure regaining compliance or continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-141847","json":"https://secwatch.observer/filing/0001193125-24-141847.json","markdown":"https://secwatch.observer/filing/0001193125-24-141847.md","text":"https://secwatch.observer/filing/0001193125-24-141847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524141847/0001193125-24-141847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524141847/d817743d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T16:47:03.784299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"338ec3255afe6152d34ebca88e4ab7c2a96b5f1a","claim":"eFFECTOR Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"May 16, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Company’s Minimum Value of Listed Securities, as defined by Nasdaq (“MVLS”), has been below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock, and its com","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524141847/0001193125-24-141847-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}